氨磺必利治疗首发精神分裂症44例临床疗效及安全性  

Clinical Effect and Safety of Amisulpride in the Treatment of 44 Patients with First-Episode Schizophrenia

作　　者：邱继红[1] 杨英杰 QIU Jihong;YANG Yingjie(Chongqing Mental Health Hospital, Chongqing, China 401147)

机构地区：[1]重庆市精神卫生中心,重庆401147

出　　处：《中国药业》2019年第3期66-68,共3页China Pharmaceuticals

摘　　要：目的探讨氨磺必利治疗首发精神分裂症患者的临床疗效。方法选择医院收治的首发精神分裂症患者44例,予氨磺必利单一治疗,随访8周。采用阳性和阴性症状量表(PANSS)评定临床疗效,精神分裂症患者生活质量量表(SQLS)评定生活质量,测定患者的体质量、体质量指数(BMI)和血催乳素水平,并统计不良反应发生情况。结果共脱落2例患者,纳入42例(95. 45%);治疗后,PANSS总分、SQLS总分、心理社会分量表总分、精力/动机分量表总分和症状/不良反应分量表总分均较基线(0周)有显著下降(P <0. 05);血催乳素水平、体质量和BMI均较基线(0周)有显著升高(P <0. 05)。结论氨磺必利可有效改善首发精神分裂症患者的精神病症状,提高其生活质量,但易引起血催乳素水平增高和体质量增加。Objective To investigate the clinical effect of amisulpride in the treatment of patients with first - episode schizophrenia. Methods Totally 44 patients with first - episode schizophrenia admitted to our hospital were treated with amisulpride alone and followed up for 8 weeks. The clinical effect was assessed by the Positive and Negative Symptoms Scale (PANSS), and the quality of life was assessed by the Schizophrenia Quality of Life Scale (SQLS). The patients' body weight, body mass index(BMI) and prolactin levels were measured, and the adverse reactions were recorded. Results 2 patients were discontinuation and 42 cases(95. 45%) were included. Compared with the baseline values(0 week), the PANSS total score, SQLS total score, psychosocial subscale total score, energy/motivation subscale total score and symptoms/adverse reactions subscale total score of the patients were significantly lower after treatment(P < 0.05), the blood prolactin level, body weight and BMI of the patients were significantly higher after treatment(P < 0. 05). Conclusion Amsulfopril can effectively improve the psychiatric symptoms and quality of life of the patients with first - episode schizophrenic, but it is easy to cause the increase of serum prolactin level and weight gain.

关 键 词：氨磺必利 精神分裂症 首发 催乳素 体质量 临床疗效 安全性 

分 类 号：R969.4[医药卫生—药理学] R971.41[医药卫生—药学]